CBD for inflammations

What anti-inflammatory effect does CBD have?

Cannabidiol (CBD), a non-psychoactive cannabinoid from the hemp plant, exhibits a remarkably broad spectrum in preclinical studies of anti-inflammatory effects. These are based on the modulation of central immune, stress, and cellular metabolism processes and are not limited to a single signaling network. Rather, CBD acts on multiple molecular levels simultaneously – an aspect that makes it particularly interesting for the supportive treatment of chronic inflammatory diseases.

Inhibition of proinflammatory cytokines

Numerous studies show that CBD reduces the expression and release of classic proinflammatory cytokines such as Tumor necrosis factor-alpha (TNF-α), Interleukin-1β (IL-1β), Interleukin-6 (IL-6) and Interferon-gamma (IFN-γ) significantly lowers. These pro-inflammatory messengers play a key role in the pathogenesis of various chronic diseases – from autoimmune disorders to neurodegenerative diseases to metabolic-inflammatory syndromes.

In a model of experimental autoimmune encephalomyelitis (EAE), an experimental form of multiple sclerosis, showed Kozela et al. (2011), that CBD inhibited the proliferation of pathogenic T cells and cytokine production. Also, in murine macrophage models, Nichols & Kaplan (2020) demonstrate the anti-inflammatory effect of CBD through a reduction in gene expression of IL-6, TNF-α, and CCL2.

Blockade of central inflammation signaling pathways

CBD specifically interferes with intracellular signaling cascades that are crucial for the inflammatory cellular response. The most important effects include:

• Inhibition of the NF-κB pathway (Nuclear Factor kappa-light-chain-enhancer of activated B cells), a central transcription factor for pro-inflammatory genes.
• Modulation of the MAPK/ERK system (Mitogen-activated protein kinase), which controls cellular stress responses.
• Suppression of the NLRP3 inflammasome, an intracellular sensor for the activation of inflammatory processes.

These mechanisms were, among others, described in the reviews by Pisanti et al. (2017) and Gugliandolo et al. (2020) described in detail and considered central pathways for the anti-inflammatory effect of CBD.

Influence on immune cell activity

Furthermore, CBD modulates the activation and differentiation of immune cells. It reduces:

• the Proliferation and cytokine secretion of T cells
• the Activation of microglia, the resident immune cells of the central nervous system
• the Proinflammation of macrophage cellsby inhibiting polarization to the M1 phenotype and supporting the anti-inflammatory M2 type

These immunomodulatory effects are particularly relevant for neuroinflammatory and autoimmune diseases – such as multiple sclerosis, rheumatoid arthritis, or chronic inflammatory bowel diseases.

Antioxidant and cell-protective properties

Another anti-inflammatory aspect of CBD is its antioxidant effect. Inflammatory processes are closely linked to oxidative stress, where reactive oxygen species (ROS) cause cell damage. CBD counteracts this process by:

• Inhibition of ROS production
• Induction of antioxidant enzymes such as Superoxide dismutase (SOD) or Heme oxygenase-1 (HO-1)
• Protection of mitochondrial function and DNA integrity

These effects were described, among others, in the review by Atalay et al. (2020) highlighted.

CBD shows a multifactorial anti-inflammatory effect profile, which goes beyond mere symptom suppression. It influences central control points of the immune system, reduces proinflammatory cytokines, modulates key signaling pathways such as NF-κB and NLRP3, and protects against oxidative stress. These effects have been described in in vitro models, animal experiments, as well as in initial clinically relevant contexts.

CBD thus has great potential as a complementary substance in the treatment of chronic inflammatory diseases. The effect is dose-dependent, context-sensitive, and should be administered under medical supervision, especially in the presence of underlying conditions or immunosuppressive therapy.

How does CBD affect chronic inflammatory diseases?

Cannabidiol (CBD) acts in chronic inflammatory diseases through multiple molecular and immunological mechanisms that are consistently demonstrated in preclinical studies and are also applied in initial clinical contexts. Chronic inflammations are characterized by a persistent, dysregulated activation of the immune system – often accompanied by oxidative stress, tissue damage, and a disturbed cytokine balance. CBD acts at several critical points here:

Modulation of the immune system

CBD shows an immunomodulatory effect without being immunosuppressive in the classical sense. It promotes the balance between pro- and anti-inflammatory immune processes:

• Reduction of pro-inflammatory cytokines such as TNF-α, IL-1β, IL-6, and IFN-γ
• Promotion of anti-inflammatory cytokines such as IL-10
• Influence on T-cell differentiation, e.g., by inhibiting Th1 and Th17 cell activity, which are central to autoimmune processes
• Suppression of microglia activation in the central nervous system (relevant for neuroinflammatory diseases)

These immunoregulatory properties were described, among others, in the review by Pisanti et al. (2017) as well as in the original works by Kozela et al. (2011) and Gugliandolo et al. (2020) documented.

Inhibition of central inflammatory signaling pathways

CBD interferes with key processes of chronic inflammation, including:

• Inhibition of the NF-κB signaling pathway, a key regulator of inflammatory gene expression
• Blockade of the NLRP3 inflammasome, which is pathologically active, among others, in rheumatoid arthritis, multiple sclerosis, and Alzheimer’s
• Modulation of the JAK/STAT and MAPK signaling pathways, both of which are involved in cell proliferation, inflammatory response, and autoimmunity

These effects act directly on the transcription of inflammatory mediators and thus on the course of chronic inflammatory processes.

Antioxidant and cell-protective effects

Chronic inflammation is closely linked to oxidative stress associated. CBD acts antioxidatively by:

• inhibits the formation of reactive oxygen species (ROS)
• the expression of protective enzymes such as SOD and HO-1 increases
• Stabilizes mitochondrial function and prevents oxidative DNA damage

These properties protect tissue from structural damage and contribute to the relief of secondary symptoms (e.g., pain, fibrosis).

Application-relevant disease models

The anti-inflammatory effect of CBD has been demonstrated in various models of chronic diseases:

CBD exerts a broad anti-inflammatory effect profile in chronic inflammatory diseases. It modulates immune responses, inhibits pro-inflammatory signaling pathways, and protects cells from oxidative stress – without the immunosuppressive depth of classical drugs. This makes it a promising candidate for complementary or additive treatment chronic inflammatory diseases. However, the application should be medically supervised and to a standardized quality pay attention to the CBD product – especially if there is an existing medication (e.g., immunosuppressants).

Can CBD help with arthritis and rheumatism?

Yes, cannabidiol (CBD) shows promising effects in preclinical and initial clinical studies for inflammatory rheumatic diseases such as arthritis and rheumatism. The underlying effects are both anti-inflammatory and pain-relieving in nature – which potentially makes CBD a complementary therapy option for chronic inflammatory joint diseases.

Mechanisms of action related to rheumatic diseases:

Inhibition of proinflammatory cytokines: Studies such as those by Kozela et al. (2011) show that CBD can significantly reduce the production of pro-inflammatory mediators like TNF-α, IL-6, and IFN-γ. These cytokines play a central role in the pathogenesis of rheumatoid arthritis.

Influence on T cells and microglia: CBD inhibits activated T helper cells of the Th1 and Th17 types, which are significantly involved in the development of autoimmune inflammation. At the same time, according to the same study, it reduces microglia activation in the central nervous system, which can decrease systemic inflammation.

Reduction of joint swelling and pain: In animal models of rheumatoid arthritis, it has been shown that CBD reduces swelling in affected joints, improves mobility, and inhibits neuropathic pain processes – among other things by modulating the TRPV1 receptor and the endocannabinoid system.

Oxidative stress and neuroinflammation: Chronic inflammations like arthritis are associated with oxidative stress. CBD acts antioxidatively here by inhibiting the activity of inflammation-relevant enzymes such as COX-2 and iNOS and reducing the production of reactive oxygen species (e.g., according to Jastrząb et al., 2020).

Clinical indications and application

• Review articles and initial clinical observations report that patients with rheumatic complaints benefit from relief of typical symptoms such as stiffness, joint pain, and nighttime restlessness through CBD – especially with regular use.
• However, a systematic clinical review like those for approved antirheumatic drugs is still pending. So far, these are off-label uses that need to be evaluated individually.
• For use in chronic rheumatic diseases, orally administered CBD products or topical preparations (e.g., CBD gels or creams) are considered.

CBD shows anti-inflammatory and pain-relieving properties in preclinical models and initial human observations for arthritis and rheumatic diseases. The data is promising but not yet sufficient for a standardized therapy recommendation. As a complementary measure – especially in therapy-resistant symptoms – CBD can be a supportive option but should be used under medical supervision.

Which studies support the use of CBD for inflammation?

Several scientifically based studies and review articles demonstrate the anti-inflammatory effects of cannabidiol (CBD) – both in preclinical models and in initial clinical approaches. Below is a selection of relevant publications supporting the use of CBD for inflammation:

How is CBD taken for inflammatory processes?

The intake of cannabidiol (CBD) for inflammatory processes depends on the treatment goal, the severity of symptoms, individual tolerance, and the chosen dosage form. Studies and reviews show that systemically available applications – especially in medium to higher dosages – are crucial for the anti-inflammatory effect.

Dosage recommendations for inflammatory diseases

Based on review articles (e.g., Pisanti et al., 2017; Nichols & Kaplan, 2020) and preclinical studies, it is considered:

• Initial dosage: approx. 10–25 mg CBD per day, to test tolerance.
• Therapeutic dosage for chronic inflammation: mostly 50–150 mg/day, depending on the clinical picture.
• For severe inflammatory processes (e.g., autoimmune diseases): Dosages up to 300 mg/day were used in studies, e.g., in multiple sclerosis or Crohn's disease.

These dosages primarily refer to pure CBD (isolate or API). With full-spectrum products, the effectiveness can be enhanced by the so-called Entourage effect (Synergy with terpenes and other cannabinoids) can influence this – however, with simultaneously increased complexity in assessing the effects.

Special instructions for intake

• Consistency is crucial: The anti-inflammatory effect of CBD unfolds not immediately, but cumulative over days to weeks.
• Slow titration: To avoid side effects, the dose should be slowly increased occur.
• Interaction with other medications: CBD can inhibit CYP450 enzymes (e.g., CYP3A4), which should be medically supervised when taken simultaneously with immunosuppressants or NSAIDs.
• Duration of use: Inflammatory processes usually require a medium- to long-term intake – CBD is therefore particularly suitable to support chronic inflammatory diseases.

CBD can be applied orally, sublingually, or topically in inflammatory processes – depending on the type and location of the inflammation. For systemic diseases, a regular intake of moderate to high doses over several weeks required. The application should be individually adjusted and ideally medically supervised – especially in autoimmune underlying diseases or simultaneous medication.

Are there experiences with CBD for intestinal inflammations such as Crohn's disease?

Cannabidiol (CBD) shows potentially anti-inflammatory effects in preclinical models as well as initial clinical observations in chronic inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. The mechanisms of action mainly include modulation of the endocannabinoid system, inhibition of proinflammatory signaling pathways such as NF-κB, and influence on receptors like CB2, GPR55, and PPARγ. These mechanisms lead to a reduction of key inflammatory mediators such as TNF-α, IL-1β, and IL-6. In animal models, it has been shown that CBD alleviates mucosal inflammation, reduces oxidative stress, and stabilizes the intestinal barrier. A small clinical pilot study in Crohn's disease patients did not show a significant improvement in remission but indicated a tendency towards symptomatic improvement and higher quality of life. Although comprehensive placebo-controlled studies are currently lacking, many affected individuals report subjective improvements such as reduced abdominal pain, less bloating, and better sleep. CBD should not be understood as a replacement for classic immunosuppressive therapy but as an adjunct measure. A therapeutic effect usually appears only with regular use at moderate doses (≥100 mg/day). Administration is in the form of oils, capsules, or rectally if needed. Medical supervision is essential with existing medication and active disease. Thus, CBD can play a supportive role in chronic inflammatory bowel diseases, especially for symptom control and improving quality of life.

What role does the endocannabinoid system play in inflammation?

The endocannabinoid system (ECS) plays a central role in regulating inflammatory processes in the human body. It consists of endogenous ligands (e.g., anandamide and 2-AG), the cannabinoid receptors CB1 and CB2, as well as the enzymes responsible for the synthesis and breakdown of endocannabinoids. Regarding inflammation, the CB2 receptor is of particular importance because it is predominantly expressed on immune cells and mediates anti-inflammatory signals there.

In response to inflammatory stimuli, the ECS is actively upregulated – especially in immune cells, microglia, mast cells, and in the gastrointestinal as well as central nervous system. Activation of the CB2 receptor by endogenous or exogenous ligands such as CBD leads to inhibition of the release of proinflammatory cytokines (e.g., TNF-α, IL-1β, IL-6), reduction of oxidative stress, and modulation of the migration and activation of immune cells. At the same time, ECS activation promotes the release of inflammation-resolving mediators and thus supports the return to immunological balance (homeostatic function).

Although cannabidiol (CBD) does not act directly as a CB2 agonist, it indirectly modulates the ECS by, for example, inhibiting the reuptake and breakdown of anandamide (FAAH inhibition), blocking GPR55 as a proinflammatory receptor, activating PPARγ, and exerting additional immunoregulatory effects via TRPV1 and 5-HT1A. This multifactorial effect explains the potentially broad anti-inflammatory benefits of CBD in various chronic inflammatory diseases. Overall, the endocannabinoid system represents a significant therapeutic target for controlling inflammation – both in the context of autoimmune, allergic, and neuroinflammatory processes.

Is CBD also effective for skin inflammations?

Yes, cannabidiol (CBD) also shows promising therapeutic potential in skin inflammations. The skin is not only a protective organ but also an active immunological tissue that has its own endocannabinoid system (ECS). This consists – analogous to other body tissues – of cannabinoid receptors (especially CB2), endogenous ligands (such as anandamide), and the corresponding enzymes. CBD interacts with these structures and can thus modulate inflammatory skin processes.

Studies show that CBD exerts anti-inflammatory, antioxidant, and antiproliferative effects on keratinocytes, T cells, and other immune cells of the skin. It inhibits proinflammatory cytokines such as IL-6 and TNF-α, reduces oxidative stress, and stabilizes the skin’s barrier function. Furthermore, it influences inflammatory signaling pathways involved in the pathogenesis of chronic inflammatory dermatoses through activation of PPARγ, TRPV1, and inhibition of GPR55.

In preclinical models as well as initial clinical studies, CBD has shown positive effects in diseases such as atopic dermatitis, psoriasis, seborrheic dermatitis, and acne. It reduces sebum production, alleviates itching, inhibits the proliferation of inflammatory cells, and contributes to the regeneration of disturbed skin areas.

Topical application of CBD in the form of creams, ointments, or lotions is particularly interesting, as these act directly on the affected skin areas and largely avoid systemic side effects. Regular use can lead to improved skin texture, reduced tendency to inflammation, and subjective relief.

CBD has a proven anti-inflammatory effect on the skin and can be used supportively in various dermatological conditions – especially in chronic inflammatory skin diseases. However, further large controlled studies are necessary to define precise dosage recommendations and indications.

What is better for inflammation – CBD oil, ointment, or capsules?

Which form of cannabidiol (CBD) is best suited for inflammations – oil, ointment, or capsules – depends largely on the type and location of the inflammation. Bioavailability, onset of action, and the desired therapeutic depth play a central role.

CBD oil (sublingual):  CBD oil, which is dropped under the tongue, acts relatively quickly (within 15–45 minutes) and has a medium to good bioavailability. This form is especially suitable for systemic inflammations, as seen in autoimmune diseases (e.g., rheumatoid arthritis, multiple sclerosis) or chronic inflammatory bowel diseases (IBD). Through direct absorption via the oral mucosa, CBD can influence the inflammatory status throughout the entire body.

CBD capsules (oral): CBD capsules are absorbed in the gastrointestinal tract and exert their effect delayed (after about 1–2 hours), but over a longer period of time. They are ideal for chronic internal inflammations, for example in Crohn's disease, ulcerative colitis, or systemic inflammatory tendency. Capsules offer standardized dosing, are tasteless, and especially practical for daily intake.

CBD ointments / creams (topical): Topical CBD applications work local and are especially effective for inflammatory skin diseases (e.g. psoriasis, atopic dermatitis, acne) or superficial joint inflammations (e.g. osteoarthritis in fingers, knees) suitable. The effect is limited to the treated region, minimizing systemic side effects. Studies show that CBD creams stabilize the skin barrier, relieve itching and redness, and can locally inhibit inflammatory processes.

Comparison of application forms for inflammation

The best form of CBD application for inflammations depends on the area of use. For systemic inflammations CBD oil or capsules are useful – depending on the desired onset of effect. For local inflammations of the skin or joints have topical ointments and creams Benefits. In many cases, a combination of internal and external application is particularly effective.

Are there risks associated with long-term use of CBD for inflammation?

Yes, with long-term use of cannabidiol (CBD) for the treatment of inflammatory diseases potential risks and side effects may occur, even though CBD is generally considered well tolerated. Current studies show that CBD can be safely used over weeks to months, especially at therapeutically relevant dosages. However, long-term experience over many years – especially in healthy individuals – is limited, which is why regular medical supervision is recommended.

Possible risks and side effects with long-term use

Special considerations in chronic inflammatory diseases

In patients with autoimmune diseases (e.g. rheumatoid arthritis, MS, Crohn's disease) long-term use of CBD as an anti-inflammatory add-on can be useful. In these cases, however, intake should always be medically supervised are, especially with simultaneous immunosuppression or corticosteroid therapy.

The long-term use of CBD for inflammation is considered well tolerated, but carries certain risks – especially with regard to Liver function and drug interactions. An individual benefit-risk assessment by an experienced physician as well as regular laboratory and therapy monitoring are strongly recommended for long-term use. For chronic inflammatory conditions, CBD can be a valuable supplement – but not a blanket self-medication without supervision.

Are there findings on CBD and prostatitis?

A promising approach for the local treatment of chronic, non-bacterial prostatitis is the use of CBD-containing rectal suppositories such as CANNEFF® SUP. These contain 100 mg cannabidiol combined with hyaluronic acid and act directly at the site of inflammation. In a pilot study with 16 patients, significant relief of typical symptoms such as pelvic pain, micturition disorders, and sexual dysfunctions was observed after 30 days of use. The effect was comparable to systemic therapies such as alpha-blockers or nonsteroidal anti-inflammatory drugs, but with the advantage of targeted, locally limited application and lower systemic side effect potential. The synergistic effect of anti-inflammatory CBD and tissue-regenerating hyaluronic acid makes CANNEFF® SUP an innovative addition in the treatment of chronic pelvic pain syndrome – especially for patients seeking a non-invasive, well-tolerated alternative to conventional medications. However, medical evaluation before starting therapy is always required.

Sources

Nagarkatti, P., Pandey, R., Rieder, S. A., Hegde, V. L., & Nagarkatti, M. (2009). Cannabinoids as novel anti-inflammatory drugs. Future medicinal chemistry, 1(7), 1333–1349. https://doi.org/10.4155/fmc.09.93

Nichols, J. M., & Kaplan, B. L. F. (2020). Immune Responses Regulated by Cannabidiol. Cannabis and cannabinoid research, 5(1), 12–31. https://doi.org/10.1089/can.2018.0073

Pisanti, S., Malfitano, A. M., Ciaglia, E., Lamberti, A., Ranieri, R., Cuomo, G., Abate, M., Faggiana, G., Proto, M. C., Fiore, D., Laezza, C., & Bifulco, M. (2017). Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacology & therapeutics, 175, 133–150. https://doi.org/10.1016/j.pharmthera.2017.02.041

Burstein S. (2015). Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorganic & medicinal chemistry, 23(7), 1377–1385. https://doi.org/10.1016/j.bmc.2015.01.059

Kozela, E., Lev, N., Kaushansky, N., Eilam, R., Rimmerman, N., Levy, R., Ben-Nun, A., Juknat, A., & Vogel, Z. (2011). Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice. British journal of pharmacology, 163(7), 1507–1519. https://doi.org/10.1111/j.1476-5381.2011.01379.x

Atalay, S., Jarocka-Karpowicz, I., & Skrzydlewska, E. (2019). Antioxidative and Anti-Inflammatory Properties of Cannabidiol. Antioxidants (Basel, Switzerland), 9(1), 21. https://doi.org/10.3390/antiox9010021

Gugliandolo, A., Pollastro, F., Bramanti, P., & Mazzon, E. (2020). Cannabidiol exerts protective effects in an in vitro model of Parkinson's disease activating AKT/mTOR pathway. Phytotherapy, 143, 104553. https://doi.org/10.1016/j.fitote.2020.104553